<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494349</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-1207-P1-PK</org_study_id>
    <nct_id>NCT02494349</nct_id>
  </id_info>
  <brief_title>The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.</brief_title>
  <official_title>Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207 and Soifenacin/Tamsulosin in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and compare the pharmacokinetic characteristics
      and safety/tolerability between JLP-1207(Solifenacin/Tamsulosin 5mg/0.2mg)and
      co-administration of Solifenacin and Tamsulosin between Solifenacin and Tamsulosin in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single dose, two-way crossover study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast, Cmax</measure>
    <time_frame>192 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>192 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>192 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>192 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>192 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/f</measure>
    <time_frame>192 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>LUTS(Lower Urinary Tract Symptoms)</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>JLP-1207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JLP-1207 dosing in the fed state(high fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin 5mg+Tamsulosin 0.2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JLP-1207</intervention_name>
    <description>The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.</description>
    <arm_group_label>JLP-1207</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin 5mg+Tamsulosin 0.2mg</intervention_name>
    <description>The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.</description>
    <arm_group_label>Solifenacin 5mg+Tamsulosin 0.2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~45 years healthy male

          -  Body weight is over 55kg, BMI measurement 18.0kg/m^2~ 27.0kg/m^2

          -  Signed informed consent form from to participate voluntarily and to comply with the
             trial requirements.

          -  Researchers determined suitable volunteers through physical examination, laboratory
             tests

        Exclusion Criteria:

          -  History of clinically significant liver, kidneys, nervous system, immune system,
             respiratory, endocrine disorders or tumor or blood disorders, cardiovascular diseases,
             mental disorders (mood disorders, obsessive-compulsive disorder, etc.)

          -  Sitting SBP&gt;150mmHg or &lt;100mmHg, sitting DBP&gt;100mmHg or &lt;60mmHg, after 3 minutes break

          -  An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

          -  Have a gastrointestinal disease history that can affect drug absorption (Crohn's
             disease ulcers, etc) or surgery (except simple appendectomy or hernia surgery)

          -  History of drug abuse

          -  Positive urine drug screening

          -  Administrated investigational product in a previous clinical trial within 90 days of
             the first administration day in this study.

          -  Donated blood within 60 days prior to the first administration day in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-sang Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital(SNUH)</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Î±1-blockers</keyword>
  <keyword>antimuscarinic agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

